[1] |
SUNG H, FERLAY J, SIEGEL R L, et al. Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3):209-249.
DOI
URL
|
[2] |
HANKER A B, SUDHAN D R, ARTEAGA C L. Overcoming endocrine resistance in breast cancer[J]. Cancer Cell, 2020, 37(4):496-513.
DOI
URL
|
[3] |
OSBORNE C K, SCHIFF R. Mechanisms of endocrine resistance in breast cancer[J]. Annu Rev Med, 2011, 62:233-247.
DOI
URL
|
[4] |
DALY M B, PAL T, BERRY M P, et al. Genetic/familial high-risk assessment:breast,ovarian,and pancreatic,version 2.2021,NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2021, 19(1):77-102.
DOI
URL
|
[5] |
LOIBL S, POORTMANS P, MORROW M, et al. Breast cancer[J]. Lancet, 2021, 397(10286):1750-1769.
DOI
URL
|
[6] |
ZHAO H, WU L, YAN G, et al. Inflammation and tumor progression:signaling pathways and targeted intervention[J]. Signal Transduct Target Ther, 2021, 6(1):263.
DOI
URL
|
[7] |
DI J, HUANG H, QU D, et al. Rap2B promotes proliferation,migration,and invasion of human breast cancer through calcium-related ERK1/2 signaling pathway[J]. Sci Rep, 2015, 5:12363.
DOI
URL
|
[8] |
YANG X, SHANG P, YU B, et al. Combination therapy with miR34a and doxorubicin synergistically inhibits Dox-resistant breast cancer progression via down-regulation of snail through suppressing Notch/NF-κB and RAS/RAF/MEK/ERK signaling pathway[J]. Acta Pharm Sin B, 2021, 11(9):2819-2834.
DOI
URL
|
[9] |
ZHU Y, LIU Y, ZHANG C, et al. Tamoxifen-resistant breast cancer cells are resistant to DNA-damaging chemotherapy because of upregulated BARD1 and BRCA1[J]. Nat Commun, 2018, 9(1):1595.
DOI
URL
|
[10] |
DU RUSQUEC P, BLONZ C, FRENEL J S, et al. Targeting the PI3K/Akt/mTOR pathway in estrogen-receptor positive HER2 negative advanced breast cancer[J]. Ther Adv Med Oncol, 2020, 12:1758835920940939.
|
[11] |
LU Y, YU Q, LIU J H, et al. Src family protein-tyrosine kinases alter the function of PTEN to regulate phosphatidylinositol 3-kinase/AKT cascades[J]. J Biol Chem, 2003, 278(41):40057-40066.
DOI
URL
|
[12] |
GEBREGIWORGIS T, KANO Y, ST-GERMAIN J, et al. The Q61H mutation decouples KRAS from upstream regulation and renders cancer cells resistant to SHP2 inhibitors[J]. Nat Commun, 2021, 12(1):6274.
DOI
URL
|
[13] |
VERRET B, CORTES J, BACHELOT T, et al. Efficacy of PI3K inhibitors in advanced breast cancer[J]. Ann Oncol, 2019, 30(Suppl 10):x12-x20.
|
[14] |
VAN DER ZWET J C G, BUIJS-GLADDINES J G C A M, CORDO' V, et al. MAPK-ERK is a central pathway in T-cell acute lymphoblastic leukemia that drives steroid resistance[J]. Leukemia, 2021, 35(12):3394-3405.
DOI
URL
|
[15] |
HAN S, REN Y, HE W, et al. ERK-mediated phosphorylation regulates SOX10 sumoylation and targets expression in mutant BRAF melanoma[J]. Nat Commun, 2018, 9(1):28.
DOI
URL
|
[16] |
MARTIN E, AGAZIE Y M. SHP2 potentiates the oncogenic activity of β-catenin to promote triple-negative breast cancer[J]. Mol Cancer Res, 2021, 19(11):1946-1956.
DOI
URL
|
[17] |
MUSCELLA A, STEFÀNO E, CALABRISO N, et al. Role of epidermal growth factor receptor signaling in a Pt(Ⅱ)-resistant human breast cancer cell line[J]. Biochem Pharmacol, 2021, 192:114702.
DOI
URL
|
[18] |
KAVARTHAPU R, ANBAZHAGAN R, DUFAU M L. Crosstalk between PRLR and EGFR/HER2 signaling pathways in breast cancer[J]. Cancers(Basel), 2021, 13(18):4685.
|
[19] |
BROWNE A L, CHARMSAZ S, VAREŠLIJA D, et al. Network analysis of SRC-1 reveals a novel transcription factor hub which regulates endocrine resistant breast cancer[J]. Oncogene, 2018, 37(15):2008-2021.
DOI
URL
|
[20] |
SIZEMORE G M, PITARRESI J R, BALAKRISHNAN S, et al. The ETS family of oncogenic transcription factors in solid tumours[J]. Nat Rev Cancer, 2017, 17(6):337-351.
DOI
URL
|
[21] |
AL-AZAWI D, ILROY M M, KELLY G, et al. Ets-2 and p160 proteins collaborate to regulate c-Myc in endocrine resistant breast cancer[J]. Oncogene, 2008, 27(21):3021-3031.
DOI
URL
|
[22] |
DE LUCA A, MAIELLO M R, D'ALESSIO A, et al. The RAS/RAF/MEK/ERK and the PI3K/AKT signalling pathways:role in cancer pathogenesis and implications for therapeutic approaches[J]. Expert Opin Ther Targets, 2012, 16(Suppl 2):S17-S27.
|
[23] |
FAN P, JORDAN V C. PERK,beyond an unfolded protein response sensor in estrogen-induced apoptosis in endocrine-resistant breast cancer[J]. Mol Cancer Res, 2022, 20(2):193-201.
DOI
URL
|
[24] |
QUAN Y, ZHANG X, BUTLER W, et al. The role of N-cadherin/c-Jun/NDRG1 axis in the progression of prostate cancer[J]. Int J Biol Sci, 2021, 17(13):3288-3304.
DOI
URL
|